SEC Filing Summary: Pro-Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pro-Pharmaceuticals, Inc. (Nevada) on September 5, 2003. The filing addresses a corporate event regarding the listing of common stock on the American Stock Exchange (AMEX). Note: The metadata provided in the request lists "GALECTIN THERAPEUTICS INC," but the filing text explicitly identifies the registrant as "PRO-PHARMACEUTICALS, INC."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing event rather than financial performance.
Material Changes
- Stock Listing Approval: The AMEX approved the listing of 26,504,805 shares of the Company's common stock ($.001 par value).
- Trading Commencement: The shares are scheduled to begin trading on the AMEX under the symbol "PRW" effective September 10, 2003.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. The document serves solely to disclose the approval of the stock listing and the subsequent press release issued on September 9, 2003.
Investor Verification Checklist
- Verify the ticker symbol "PRW" on the AMEX for trading commencement on September 10, 2003.
- Confirm the total number of shares approved for listing (26,504,805).
- Review the attached press release (Exhibit 99.1) for additional context on the listing.
- Clarify the discrepancy between the request metadata (Galectin Therapeutics) and the filing registrant (Pro-Pharmaceuticals).